银行理财投资A股踟蹰不前 监管部门多线调研听取业界声音

Group 1 - The core viewpoint emphasizes the importance of facilitating long-term capital market entry, as highlighted by the recent regulatory focus on gathering industry feedback to enhance investment and financing coordination in the capital market [1][2][3] - Regulatory bodies have conducted surveys with wealth management companies to identify barriers to increasing A-share investments and to gather insights on policy optimization for the next five years [2][3] - The surveys reflect a keen interest in understanding the effectiveness of existing policies and the experiences of wealth management firms, particularly regarding the impact of previous guidelines on long-term capital market participation [3] Group 2 - Wealth management firms are exploring various methods to increase equity asset allocation, including a significant rise in index-based investment products, with 98 non-structured products containing "index" as of January 6, 2026, compared to only 11, 12, and 17 in previous years [4] - The new IPO underwriting regulations set to be implemented in 2025 are expected to provide substantial policy benefits for wealth management companies participating in new stock subscriptions, with recent participation in several A-share IPOs [4][5] - Despite the ongoing exploration of equity investments, the proportion of equity assets in wealth management remains low, with only 2.1% of total investment assets allocated to equity as of Q3 2025 [7] Group 3 - The total market size of wealth management products reached 32.13 trillion yuan, with mixed products accounting for 0.83 trillion yuan (2.58%), and equity products only 0.07 trillion yuan (0.22%) [7] - The primary investment focus of wealth management products is still on fixed-income assets, with significant allocations to bonds, cash, and bank deposits, indicating a conservative investment approach [7] - Analysts believe that with regulatory support, wealth management firms are likely to further explore equity products and asset allocation, potentially evolving into long-term patient capital [8]